The purpose of this research study is to determine the safety and efficacy of administering
two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed
later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around
the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma
at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.